



Weekly Report on Severe Acute Respiratory Infection (SARI), Week 41 2022 (week ending 16/10/2022)

SARI hospitalised cases that were admitted to St. Vincent's University Hospital (SVUH), Dublin, during the fourth COVID-19 pandemic wave (05/07/2021 and 18/12/2021) and fifth wave (19/12/2021 – 16/10/2022). Please note that this report on SARI surveillance pertains to one hospital site only, data are not nationally representative. Therefore caution is advised when interpreting rates and trends as outlined in the report, which may fluctuate due to the low case numbers.

Key points

- In week 41 2022 (week ending 16/10/2022):
 - There were 12 SARI cases reported in week 41 2022, a slight decrease compared to 14 SARI cases reported during week 40 2022
 - The incidence rate per emergency hospitalisations was 42.7 per 1,000 emergency admissions, a decrease compared to 50 per 1,000 during week 40 2022
 - The incidence rate per hospital catchment population was 3.9 per 100,000 population aged ≥15 years, a decrease compared to the rate of 4.6 per 100,000 in week 40 2022
 - The highest proportion of SARI cases was among those aged 65 years and older (n=11; 91.7%)
 - Among SARI cases admitted in week 41 2022, all 12 cases were reported as having underlying medical conditions
 - SARS-CoV-2 PCR testing was carried out on all SARI cases, of which four (33.3%) were positive, compared to 15.4% positivity (n=2 of 13 tested) in week 40 2022
 - Influenza PCR testing was carried out on 11 SARI cases, all of which tested negative for influenza. One (7.7%) SARI case tested positive for influenza A (not subtyped) in week 40 2022.
 - Respiratory syncytial virus (RSV) PCR testing was carried out on 11 SARI cases, all of which tested negative, compared to 7.7% (n=1) positivity in week 40 2022
- There were 523 SARI cases admitted to St. Vincent's University Hospital (SVUH) between 19/12/2021 to 16/10/2022 (Omicron, wave 5), compared to 230 SARI cases admitted between 05/07/2021 and 18/12/2021 (Delta, wave 4)
 - The median age of SARI cases admitted during wave 5 was 75 years (interquartile range (IQR): 62 - 83 years), compared to 64 years (IQR: 48-78 years) during wave 4
 - Among SARI cases admitted during wave 5, 94.3% (n=493) reported having underlying medical conditions, compared to 81.3% (n=187) during wave 4
 - Among SARI cases for whom admission to ICU is known, 56.7% (255/450) were reported to have been admitted to ICU and/or required respiratory support during wave 5, compared to 62.4% (143/229) during wave 4
 - Among SARI cases admitted during the 5th wave (since 19/12/2021), who tested positive by PCR for SARS-CoV-2 with known COVID-19 vaccination status, 12.2% (21/172) were not vaccinated, and 34.3% (n=59) had not received a booster vaccine dose >7 days prior to their illness
 - Of those discharged, with known outcome, admitted during wave 5, 10.4% (n=43) died in hospital, compared to 10.1% (n=23) during wave 4

Table of Contents

Key points.....	1
Background	3
Methods.....	3
Results	5
SARI cases and incidence rates.....	5
Demographics.....	6
Underlying medical conditions and risk factors	7
Symptoms.....	8
Severe clinical course during hospitalisation	9
Laboratory testing for SARS-CoV-2, influenza and RSV	10
COVID-19 Vaccination status.....	12
Outcome	14
Acknowledgements.....	15
Technical notes.....	16
Appendix.....	18
Table A1.....	18
Table A2.....	19

Background

Severe acute respiratory infection (SARI) is of major relevance to public health worldwide. Surveillance of SARI is essential to monitor the (co-) circulation of respiratory pathogens and to assess disease severity. Data collected as part of SARI surveillance can provide important early warning information in the context of respiratory disease outbreaks and pandemics. SARI data can also be used as a platform to measure vaccine and antiviral effectiveness and impact.

The objectives of SARI surveillance are:

- To describe the number and incidence of SARI cases by aetiology, time, place and person
- To describe and monitor trends, intensity of activity and severity of SARI infections
- To identify groups at risk of severe disease
- To detect unusual and unexpected events
- To assess the SARI burden of disease in the participating hospital
- To assess and monitor vaccine and antiviral effectiveness

Methods

SARI surveillance was implemented in one tertiary care adult hospital; St. Vincent's University Hospital, Dublin (SVUH). Surveillance commenced on the 5th of July 2021. SARI cases are identified from new admissions through the Emergency Department (E/D). The SARI surveillance system includes people who are aged 15 years or older.

Case definition

SARI cases are identified from new admissions through the Emergency Department, based on clinical symptoms. Patients that develop SARI during their admission, or are admitted through alternate routes, are not included in the surveillance system.

Clinical SARI case:

The European Centre for Disease Prevention and Control (ECDC) clinical SARI case definition is currently used for the SARI surveillance project in Ireland:

- ECDC SARI definition: A hospitalised (defined as hospitalised for at least 24 hours) person with acute respiratory infection, with at least one of the following symptoms: cough, fever, shortness of breath OR sudden onset of anosmia, ageusia or dysgeusia with onset of symptoms within 14 days prior to hospital admission.

The ECDC clinical SARI case definition has been used for the SARI surveillance project since week 34 2021. The World Health Organization (WHO) clinical SARI case definition was used from week 27 to week 33 2021. The WHO SARI definition is defined as follows A hospitalised* person with an acute respiratory infection, and history of fever or measured fever of $\geq 38^{\circ}\text{C}$, and cough, and onset within the last 10 days.

Denominator data

Denominator data for hospital catchment area are based on population projections for 2021. Population projections are provided by the Health Intelligence Unit (HIU) of the Health Service Executive (HSE) and were extracted from Health Atlas Ireland on 31/08/2021.

Denominator data on all-cause hospital admissions, via the Emergency Department, were provided by the SVUH statistics department.

Data collection and reporting

Clinical data were collected and managed using REDCap electronic data capture tools hosted at University College Dublin. Laboratory data is extracted from APEX, the laboratory information management system (LIMS), using IBM Cognos software hosted at SVUH.

Case-based data are reported by SVUH to the HSE Health Protection Surveillance Centre (HPSC) on a weekly basis. Data are also reported by HPSC to ECDC via The European Surveillance System (TESSy) on weekly basis as part of European level SARI surveillance.

COVID-19 vaccination data were collected from the National COVID-19 Vaccination Management System (COVAX), and linked to SARI cases by the HSE-Integrated Information service, where data were available.

Reference dates¹

05/07/2021 (Week 27 2021) – Commencement of SARI surveillance project

27/06/2021 (Week 26 2021) – the beginning of the 4th COVID-19 pandemic wave

19/12/2021 (Week 51 2021) – the beginning of the 5th COVID-19 pandemic wave

Week number refers to the week of hospital admission. Weeks run from Monday to Sunday, as per the international ISO week².

¹ Refer to [Health Protection Surveillance Centre \(hpsc.ie\)](https://www.hpsc.ie) for further details on the COVID-19 pandemic waves in Ireland

² Monday to Sunday (ISO week) used as per ECDC/WHO/international reporting protocol

Results

SARI cases and incidence rates

In total, 523 SARI cases were admitted to St. Vincent’s University Hospital (SVUH) during the fifth pandemic wave (between 19/12/2021 and 16/10/2022); 230 SARI cases were admitted during the fourth pandemic wave (between 05/07/2021 to 18/12/2021).

In week 41 2022:

- 12 SARI cases were reported in week 41 2022, compared to 14 SARI cases reported in week 40 2022 (Figure 1).
- The SARI incidence rate was 3.9 per 100,000 hospital catchment population aged ≥15 years, compared to the rate of 4.6 per 100,000 in week 40 2022.
- The SARI incidence rate per emergency hospitalisations was 42.7 per 1,000, compared to the rate of 50 per 1,000 in week 40 2022.




Figure 1 Number and incidence of SARI hospitalised cases (emergency admission) by week of hospital admission, week 27 2021 to week 41 2022 (n=753).

NOTE: Data were extracted from the SARI surveillance database at HPSC on 19/10/2022, and are subject to ongoing review, validation and update. As a result, figures in this report may differ from previously published figures.

Demographics

In week 41 2022, of the 12 SARI cases reported:

- Males accounted for a higher proportion of SARI cases (n=7, 58.3%) (Table 1)
- The median age of SARI cases admitted was 78 years (interquartile range: 71 - 83 years)
- The incidence rate amongst those aged 65 years and older was 18.4 per 100,000, stable compared to the rate of 18.4 per 100,000 in week 40 2022.

Table 1 Number and proportion of SARI cases by sex and age, for week 41 2022 and by pandemic wave.

		Week 41, 2022		Wave 5		Wave 4	
		n	%	n	%	n	%
Total number of SARI cases		12		523		230	
Sex	Male	7	58.3	278	53.2	120	52.2
	Female	5	41.7	245	46.8	110	47.8
Age (years)	Mean	77		71		63	
	Median	78		75		64	
	Interquartile range	71 - 83		62 - 83		48 - 78	
	Range	57 - 93		16 - 101		19 - 100	
Age group	15-24 years	0	0.0	14	2.7	5	2.2
	25-34 years	0	0.0	13	2.5	12	5.2
	35-44 years	0	0.0	15	2.9	27	11.7
	45-54 years	0	0.0	39	7.5	33	14.3
	55-64 years	1	8.3	66	12.6	40	17.4
	65-74 years	3	25.0	104	19.9	44	19.1
	75-84 years	6	50.0	162	31.0	39	17.0
85+ years	2	16.7	110	21.0	30	13.0	

*Surveillance excludes children under 15 years of age

The incidence rate per 100,000 hospital catchment population by age group is shown in Figure 2.




Figure 2 SARI incidence rate per 100,000 hospital catchment population by age group and week of hospital admission, week 27 2021 to week 41 2022 (n=753)

Underlying medical conditions and risk factors

Information on underlying medical conditions was reported for 748 (99.3%) SARI cases. Of those admitted during wave 5, 94.3% (n=493) reported having underlying medical conditions, compared to 81.3% (n=187) during wave 4.

Table 2 displays the number and proportion of individual underlying medical conditions, where known, among those that reported having underlying medical conditions. The most common underlying medical conditions reported during wave 5 were heart disease (n=204, 41.4%) and hypertension (n=194, 39.4%); which were also observed during wave 4.

Among female SARI cases admitted during wave 5, four (1.6%) were reported as being pregnant at the time of admission, compared to 1.8% (n=2) female SARI cases during wave 4.

Healthcare workers accounted for 2.5% (n=13) of SARI cases admitted during wave 5, compared to 4.8% (n=11) during wave 4.

Table 2 Number and proportion of SARI cases with pre-existing conditions, reported on hospital admission, for week 41 2022 and by pandemic wave.

Underlying medical condition*	Week 41 2022 (n=12)		Wave 5 (n=493)		Wave 4 (n=187)	
	n	%	n	%	n	%
Heart disease	7	58.3	204	41.4	57	30.5
Hypertension	7	58.3	194	39.4	75	40.1
Lung disease	4	33.3	165	33.5	55	29.4
Cancer	4	33.3	105	21.3	38	20.3
Neurological disease	3	25.0	90	18.3	34	18.2
Asthma	1	8.3	66	13.4	28	15.0
Diabetes	3	25.0	79	16.0	37	19.8
Kidney disease	0	0.0	35	7.1	20	10.7
Intellectual disability	0	0.0	24	4.9	14	7.5
Immunocompromised	0	0.0	16	3.2	7	3.7
Obesity	2	16.7	14	2.8	20	10.7
Cystic fibrosis	0	0.0	3	0.6	2	1.1
Other chronic conditions**	6	50.0	233	47.3	120	64.2

*SARI cases could be reported with one or more underlying medical condition

** Data reported on other chronic conditions may include some of the chronic conditions listed above; these data are under review and may change over time.

Symptoms

Information on clinical symptoms, either at or prior to hospital admission, was reported for all SARI cases. The most common symptoms during both waves 4 and 5, were cough and shortness of breath (Table 3).

Table 3 Number and proportion of SARI cases with clinical symptoms, either at or prior to hospital admission, for week 41 2022 and by pandemic wave.

Clinical symptom*	Week 41 2022 (n=12)		Wave 5 (n=523)		Wave 4 (n=230)	
	n	%	n	%	n	%
Cough	11	91.7	403	77.1	206	89.6
Shortness of breath	9	75.0	384	73.4	190	82.6
Fever	7	58.3	246	47.0	117	50.9
General deterioration	6	50.0	202	38.6	88	38.3
Malaise	0	0	72	13.8	67	29.1
Headache	1	8.3	33	6.3	29	12.6
Muscular pain	0	0	35	6.7	21	9.1
Sore throat	0	0	38	7.3	12	5.2
Ageusia	0	0	4	0.8	16	7.0
Anosmia	0	0	4	0.8	13	5.7
Dysgeusia	0	0	7	1.3	7	3.0

*SARI cases could be reported with one or more clinical symptom

Severe clinical course during hospitalisation

Information on the clinical course during hospitalisation is only available after discharge; information on ICU admission is available prior to discharge.

In summary, 79.2% (n=414) of SARI cases admitted during wave 5 have discharge information available, compared to 99.1% (n=228) during wave 4.

Among those for whom discharge information is available, and who were admitted during wave 5, 12.8% (n=53) were reported as having pneumonia, compared to 28.5% (n=65) during wave 4 (Table 4).

Information on ICU admission is available for 86% (n=450) of SARI cases admitted during wave 5 and 99.6% (n=229) of those admitted during wave 4. Among those, 56.7% (n=255) were admitted to ICU and/or required respiratory support during wave 5, compared to 62.4% (n=143) admitted during wave 4.

Data collection is ongoing for those not yet discharged from hospital.

Table 4 Number and proportion of SARI cases by complication, respiratory support and ICU admission, for wave 4 and wave 5

Complications*	Wave 5 (n=414)		Wave 4 (n=228)	
	n	%	n	%
Pneumonia	53	12.8	65	28.5
Sepsis	11	2.7	5	2.2
ARDS	41	9.9	5	2.2
Myocarditis	0	0.0	2	0.9
Long COVID	1	0.2	1	0.4
Multiorgan failure	1	0.2	0	0.0
Other complications**	108	26.1	44	19.3
No complications	226	54.6	128	56.1
Unknown	7	1.7	2	0.9
Respiratory support	Wave 5 (n=410)		Wave 4 (n=229)	
	n	%	n	%
High-flow oxygen therapy (non-invasive ventilation)	240	58.5	126	55.0
Invasive ventilation	14	3.4	17	7.4
Other respiratory support	0	0.0	0	0.0
No respiratory support given	156	38.0	86	37.6
Admitted to ICU	Wave 5 (n=450)		Wave 4 (n=229)	
	n	%	n	%
Yes	21	4.7	19	8.3
No	429	95.3	210	91.7

*SARI cases could be reported with one or more complication

**Data reported on “other complications” may include some of the complications listed above; these data are under review and may change over time.

Laboratory testing for SARS-CoV-2, influenza and RSV

PCR testing:

SARS-CoV-2 PCR testing is carried out on admission. For a small proportion of SARI cases, there is a lag time with testing for influenza and RSV³.

In week 41 2022:

- SARS-CoV-2 PCR testing was carried out on all SARI cases, four (33.3%) of which were positive, compared to 15.4% positivity (n=2 of 13 tested) in week 40 2022 (Figure 3)
- Influenza PCR testing was carried out on 11 SARI cases, all of which were negative, compared to 7.7% (n=1, influenza A; not subtyped) positivity in week 40 2022
- RSV PCR testing was carried out on 11 SARI cases, all of which were negative, compared to 7.7% (n=1) positivity in week 40 2022.




Figure 3 Percentage of SARI cases with a positive laboratory test result for SARS-CoV-2, influenza and RSV by week, weeks 27 2021 - 41 2022

Of those admitted to SVUH during wave 5, 39.3% (n=201) tested positive by PCR for SARS-CoV-2, compared to 57.2% (n=131) during wave 4 (Table 5).

During wave 5, 4.2% (n=20) of those admitted were positive for influenza A: 17 influenza A(H3) and 3 A (not subtyped), and two cases had a positive test result for both SARS-CoV-2 and influenza A, one of which was subtyped as influenza A(H3). No SARI cases admitted during wave 4 tested positive for influenza.

³ Due to reagent supply issues, samples are occasionally sent to external laboratories for influenza and RSV testing.

During wave 5, 0.8% (n=4) of those admitted were positive for RSV, compared to 3.6% (n=6) during wave 4, one of which, had a positive test result for both RSV and SARS-CoV-2.

Table 5 Number and proportion of SARI cases by laboratory test result, for week 41 2022 and by pandemic wave

Laboratory test	Laboratory test result	Week 41 2022		Wave 5		Wave 4	
		n	%	n	%	n	%
Tested for SARS-CoV-2	Total tested	12		512		229	
	Positive	4	33.3	201	39.3	131	57.2
	Negative	7	58.3	285	55.7	90	39.3
	Indeterminate*	1	8.3	26	5.1	8	3.5
Tested for influenza A	Total tested	11		479		165	
	Positive	0	0.0	20	4.2	0	0.0
	Negative	11	100	459	95.8	165	100
Tested for influenza B	Total tested	11		479		165	
	Positive	0	0.0	0	0.0	0	0.0
	Negative	11	100	479	100	165	100
Tested for RSV	Total tested	11		479		165	
	Positive	0	0.0	4	0.8	6	3.6
	Negative	11	100	475	99.2	159	96.4

* Ct value (cycle threshold) >30

Genomic analysis:

SARS-CoV-2:

SARI samples that are positive for SARS-CoV-2 and that have a cycle threshold (Ct) value <25 are referred to the National Virus Reference Laboratory (NVRL) for whole genome sequencing (WGS). In total, for both waves 4 and 5, 254 (76.5%) SARS-CoV-2 positive SARI samples have met the Ct criteria for WGS; 225 (88.6%) have been sent for WGS, 2 (0.8%) samples are waiting to be sent and 27 (10.6%) SARI samples that met the Ct eligibility criteria were not sent for WGS, for reasons such as insufficient sample volume, or the sample could not be located.

Of the 225 samples sent to NVRL for WGS, results have been received for 199 (88.4%) samples, 12 (5.3%) samples could not be sequenced (due to insufficient sample volume or high Ct value), and 14 (6.2%) are currently being sequenced and results are pending.

All SARI cases that have undergone whole genome sequencing up to week 47 2021 were Delta (B.1.617.2) and Delta sublineages. In total, 31.7% (63 of 199) of all sequenced SARI cases reported since July 2021 (weeks 28 2021 to week 33 2022) were identified as Delta variant. The last Delta variant SARI case was detected in week 1 2022.

The first Omicron variant was identified in one SARI case admitted to SVUH in week 48 2021. Between weeks 2 and 33 2022 inclusive, all SARI cases sequenced and reported from the NVRL were Omicron variants, in total 68.3% (136 of 199) of sequenced SARI cases were identified as Omicron. Figure 4 shows sequenced SARI cases by week of hospitalisation and Pango Lineage, further information on Pango Lineage is available in the appendix (Table A1).

Further sequencing data on cases admitted since week 33 2022, are not yet available.




Figure 4 Number of SARI cases sequenced and reported by the National Virus Reference Laboratory, by week of hospitalisation, week 27 2021 to week 33 2022, (n=199)

COVID-19 Vaccination status

Amongst the SARI cases, admitted during wave 5 (since 19/12/2021), who tested positive by PCR for SARS-CoV-2 with known COVID-19 vaccination status, 12.2% (21/172) were not vaccinated and 34.3% (n=59) had not received either a first or second booster vaccine dose >7 days prior to the epidemiological date of their episode of illness. (Table 6).

Vaccination data are available approximately one week after cases are notified, therefore the vaccination status for the current week’s SARI cases is recorded as unknown.

Refer to the technical notes for the full list of definitions regarding epidemiological date and COVID-19 vaccination status⁴.

NOTE: Data are provisional and subject to ongoing review, validation and update.

⁴ Refer to www.hse.ie for further information on the COVID-19 vaccination rollout.

Table 6 Number and proportion of SARI cases by COVID-19 vaccination status, SARS-CoV-2 PCR result and date of hospitalisation

SARS CoV-2 PCR positive	Admitted since rollout of second booster ¹ (n=209)		Admitted since rollout of first booster ² (n=555)		Admitted during wave 5 ³ (n=416)		Admitted during wave 4 ⁴ (n=204)	
	Vaccine status	n	%	n	%	n	%	n
Not vaccinated	9	12.9	54	20.3	21	12.2	48	40.3
Primary series - Partial	0	0.0	1	0.4	1	0.6	2	1.7
Primary series - Complete	8	11.4	95	35.7	37	21.5	66	55.5
First booster	42	60.0	105	39.5	102	59.3	3	2.5
Second booster	11	15.7	11	4.1	11	6.4	0	0.0
Total	70	100	266	100	172	100	119	100
SARS CoV-2 PCR negative								
Vaccine status	n	%	n	%	n	%	n	%
Not vaccinated	3	2.2	14	4.8	9	3.7	9	10.6
Primary series - Partial	0	0.0	0	0.0	0	0.0	1	1.2
Primary series - Complete	12	8.6	53	18.3	29	11.9	59	69.4
First booster	89	64.0	187	64.7	171	70.1	16	18.8
Second booster	35	25.2	35	12.1	35	14.3	0	0.0
Total	139	100	289	100	244	100	85	100

¹The second COVID-19 vaccination booster was rolled out on 22/04/2022

²The first COVID-19 vaccination booster was rolled out on 27/09/2021

³Wave 5 from 19/12/2021 to present; ⁴Wave 4 from 05/07/2021 to 18/12/2021

Table 7 displays the clinical course and outcome of those admitted during wave 5 by SARS CoV-2 PCR result and vaccination status. Data collection for clinical course and outcome is on-going for those admitted during wave 5.

Further information on those admitted during wave 4 is available in the appendix (Table A2).

Table 7 Number and proportion of SARI cases, admitted during wave 5 (19/12/2021 to 16/10/2022), by COVID-19 vaccination status, and SARS-CoV-2 PCR result (n=416)

SARS CoV-2 PCR positive	Required respiratory support		ICU admission		Died in hospital			
	Vaccination status	n	%	n	%	n	%	
Not vaccinated	21	12.2	11	13.3	1	16.7	1	6.3
Primary series - Partial	1	0.6	1	1.2	0	0.0	0	0.0
Primary series - Complete	37	21.5	21	25.3	2	33.3	5	31.3
First booster	102	59.3	45	54.2	2	33.3	9	56.3
Second booster	11	6.4	5	6.0	1	16.7	1	6.3
Total	172	100	83	100	6	100	16	100
SARS CoV-2 PCR negative								
Vaccination status	n	%	n	%	n	%	n	%
Not vaccinated	9	3.7	4	3.2	0	0.0	0	0.0
Primary series - Partial	0	0.0	0	0.0	0	0.0	0	0.0
Primary series - Complete	29	11.9	17	13.5	1	14.3	3	17.6
First booster	171	70.1	92	73.0	6	85.7	13	76.5
Second booster	35	14.3	13	10.3	0	0.0	1	5.9
Total	244	100	126	100	7	100	17	100

Outcome

Of the 523 SARI cases admitted during wave 5, 79.2% (n=414) have been discharged (Table 8). During wave 4, 230 SARI cases were admitted to St Vincent's University Hospital, 99.1% (n=228) of these cases have been discharged.

Of the 43 cases admitted during wave 5, who died in hospital, 31 (72.1%) were male and 12 (27.9%) were female. The median age was 82 years (interquartile range 77 – 88 years).

Of the 23 cases admitted during wave 4, who died in hospital, 17 (73.9%) were male and six (26.1%) were female. The median age was 85 years (interquartile range 73 – 91 years).

Table 8 Number and proportion of discharged SARI cases by outcome and hospital length of stay and by pandemic wave.

		Wave 5 (n=414)		Wave 4 (n=228)	
		n	%	n	%
Outcome	Discharged alive	361	87.2	200	87.7
	Transferred to another hospital	10	2.4	5	2.2
	Died in hospital	43	10.4	23	10.1
Hospital length of stay (number of days)	Mean	12		13	
	Median	6		6	
	Interquartile range	3 - 13		3 - 13	
	Range	1 - 123		1 - 203	

Acknowledgements

Sincere thanks are extended to all those who participate in SARI surveillance, including those in St. Vincent's University Hospital, the UCD Clinical Research Centre and the National Virus Reference Laboratory. Thanks to members of the HSE Integrated Information Services (IIS) for work on the SARI-COVAX data linkages.

Thanks also to Melissa Brady and Naomi Petty-Saphon, HPSC, for work on establishing the SARI surveillance pilot project.

This report was produced by the SARI surveillance team at HPSC: Róisín Duffy, Adele McKenna, Lisa Domegan, Joan O'Donnell.

Technical notes

1. SARI case

A SARI case refers to an individual patient episode of care.

2. Epidemiological date

Epidemiological date is used to determine timing of Severe Acute Respiratory Infections. Epidemiological date is based on the earliest date available on the case, taken from date of onset of symptoms, laboratory specimen collection date, and date of hospitalisation.

3. Vaccination status

For the purposes of SARI surveillance, vaccination status of cases is as follows:

- **Primary vaccination series – Partial completion, if:**
 - Received one dose of a recommended two-dose vaccine schedule and the epidemiological date is ≥ 14 days after receipt of dose one.
 - Date of receipt of dose two of a recommended two-dose vaccine schedule is < 14 days before the epidemiological date.
 - No identifiable linked record on the National COVID-19 Immunisation system, of receiving dose two of a recommended two-dose COVID-19 vaccine schedule.
- **Primary vaccination series - Complete, if:**
 - Received one dose of a recommended one-dose vaccine schedule, and the epidemiological date is ≥ 14 days after receipt of the dose.
 - Received two doses of a recommended two-dose vaccine schedule, and the epidemiological date is ≥ 14 days after receipt of the second dose.
 - Received three doses of a recommended three-dose vaccine schedule, and the epidemiological date is > 7 days after receipt of the third dose. The recommended primary series for immunocompromised individuals is three doses of a recommended vaccine.
 - Date of receipt of first booster dose is ≤ 7 days before the epidemiological date.
 - There is no identifiable linked record on the National COVID-19 Immunisation system of receiving a booster dose of a recommended COVID-19 vaccine schedule.
- **First booster dose, if:**
 - They had a first booster dose of a recommended vaccine schedule, and the epidemiological date is > 7 days after receipt of the booster dose.
 - Date of receipt of second booster dose is ≤ 7 days before the epidemiological date.
 - There is no identifiable linked record on the National COVID-19 Immunisation system of receiving a second booster dose of a recommended COVID-19 vaccine schedule.
- **Second booster dose, if:**
 - They had a second booster dose of a recommended vaccine schedule, and the epidemiological date is > 7 days after receipt of the booster dose.

- **Not vaccinated**, if the following applies:
 - Vaccination record on the National COVID-19 Immunisation system indicates the person was vaccinated after the epidemiological date.
 - The SARI patient was reported as not vaccinated on the SARI hospital clinical questionnaire, and there is no identifiable linked record of COVID-19 vaccination on the National COVID-19 Immunisation system.

- **Vaccine status unknown**, if:
 - The SARI patient is reported on the SARI hospital clinical questionnaire as vaccinated, however there is no identifiable linked record of COVID-19 vaccination on the National COVID-19 Immunisation system. Vaccination status is reported as unknown, until verified on the National COVID-19 Immunisation system.
 - The SARI patient is reported on the SARI hospital clinical questionnaire as vaccination status unknown, AND there is no identifiable linked record of COVID-19 vaccination on the National COVID-19 Immunisation system

Appendix

Table A1

Number and proportion of SARI cases sequenced and reported by the National Virus Reference Laboratory, by Pango lineage, SARI cases week 27 2021 to week 33, 2022, (n=199)

Virus variant	Number of cases	% sequenced cases
Total sequenced	199	
Delta and Delta sublineages:	63	31.7
AY.4	30	15.1
AY.43	9	4.5
B.1.617.2	5	2.5
AY.122	4	2.0
AY.5	4	2.0
AY.4.5	2	1.0
AY.4.6	2	1.0
AY.4.2.2	1	0.5
AY.6	1	0.5
AY.4.10	1	0.5
AY.46.6	1	0.5
AY.98	1	0.5
AY.4.2*	2	1.0
Omicron sublineages	136	68.3
BA.1 lineages:		
BA.1	22	11.1
BA.1.1	14	7.0
BA.2 lineages:		
BA.2	40	20.1
BA.2.9	6	3.0
BA.2.3	5	2.5
BA.2.1	1	0.5
BA.2.12.1	1	0.5
BA.2.18	1	0.5
BA.2.40.1	1	0.5
BA.4 lineages:		
BA.4	3	1.5
BA.4.1	1	0.5
BA.4.4	1	0.5
BA.5 lineages:		
BA.5.1	18	9.0
BA.5.2.1	6	3.0
BA.5	5	2.5
BA.5.2	5	2.5
BE.1	4	2.0
BA.5.3	1	0.5
BF.1	1	0.5

* Variant of interest

Table A2

Number and proportion of SARI cases, admitted during wave 4 (05/07/2021 to 18/12/2021), by COVID-19 vaccination status, and SARS-CoV-2 PCR result (n=204)

SARS CoV-2 PCR positive			Required respiratory support		ICU admission		Died in hospital	
Vaccination status	n	%	n	%	n	%	n	%
Not vaccinated	48	40.3	38	48.1	7	43.8	4	26.7
Primary series - Partial	2	1.7	1	1.3	0	0.0	0	0.0
Primary series - Complete	66	55.5	37	46.8	8	50.0	10	66.7
First booster	3	2.5	3	3.8	1	6.3	1	6.7
Second booster	0	0.0	0	0.0	0	0.0	0	0.0
Total	119	100	79	100	16	100	15	100
SARS CoV-2 PCR negative								
Vaccination status	n	%	n	%	n	%	n	%
Not vaccinated	9	10.6	6	13.0	0	0.0	0	0.0
Primary series - Partial	1	1.2	1	2.2	1	33.3	0	0.0
Primary series - Complete	59	69.4	32	69.6	1	33.3	5	71.4
First booster	16	18.8	7	15.2	1	33.3	2	28.6
Second booster	0	0.0	0	0.0	0	0.0	0	0.0
Total	85	100	46	100	3	100	7	100